SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC
Position in IONS — Ionis Pharmaceuticals Inc
CIK 1638555
Boston, MA
Position in IONS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$105,428,837
-$10,285,834 QoQ
Shares Held
1,404,033
-4.0% QoQ
Ownership
0.850%
of shares outstanding
% of Portfolio
4.95%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 78.32194827329558.ToString("F0")%
Shared 0.ToString("F0")%
None 21.678051726704428.ToString("F0")%
Common Shares in IONS Over Time
Shares Held
Position Value (USD)
Derivatives in IONS
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$33,790,500
PutShares
450,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds $272,348,421 across 4 Biotechnology names. IONS ranks #2 (38.7% of the industry book) .
All Filings in IONS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $33,790,500 | 450,000 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $105,428,837 | 1,404,033 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $23,733,000 | 300,000 | Put | Sole | 2026-02-17 | |
| 2025-12-31 | $115,714,671 | 1,462,706 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $39,193,122 | 599,100 | Call | Sole | 2025-11-14 | |
| 2025-09-30 | $49,065,000 | 750,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||